- Home
- CUE vs ANIX Comparison
CUE vs ANIX Comparison
Compare CUE & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- ANIX
- Stock Information
- Founded
- CUE 2014
- ANIX 1982
- Country
- CUE United States
- ANIX United States
- Employees
- CUE N/A
- ANIX N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- ANIX Health Care
- Exchange
- CUE Nasdaq
- ANIX Nasdaq
- Market Cap
- CUE 48.0M
- ANIX 108.9M
- IPO Year
- CUE 2018
- ANIX 1987
- Fundamental
- Price
- CUE $0.68
- ANIX $3.23
- Analyst Decision
- CUE Strong Buy
- ANIX Strong Buy
- Analyst Count
- CUE 3
- ANIX 3
- Target Price
- CUE $3.00
- ANIX $9.00
- AVG Volume (30 Days)
- CUE 311.2K
- ANIX 242.7K
- Earning Date
- CUE 08-13-2025
- ANIX 05-28-2025
- Dividend Yield
- CUE N/A
- ANIX N/A
- EPS Growth
- CUE N/A
- ANIX N/A
- EPS
- CUE N/A
- ANIX N/A
- Revenue
- CUE $7,991,000.00
- ANIX N/A
- Revenue This Year
- CUE N/A
- ANIX N/A
- Revenue Next Year
- CUE $23.84
- ANIX N/A
- P/E Ratio
- CUE N/A
- ANIX N/A
- Revenue Growth
- CUE 13.83
- ANIX N/A
- 52 Week Low
- CUE $0.45
- ANIX $2.07
- 52 Week High
- CUE $1.99
- ANIX $4.20
- Technical
- Relative Strength Index (RSI)
- CUE 47.91
- ANIX 51.86
- Support Level
- CUE $0.65
- ANIX $3.18
- Resistance Level
- CUE $0.71
- ANIX $3.33
- Average True Range (ATR)
- CUE 0.08
- ANIX 0.22
- MACD
- CUE 0.00
- ANIX -0.05
- Stochastic Oscillator
- CUE 38.62
- ANIX 13.94
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.